FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147596827> ?p ?o ?g. }

• W2147596827 endingPage "1276.e4" @default.
• W2147596827 startingPage "1267" @default.
• W2147596827 abstract "A phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C virus (HCV) genotype 2/3.In all, 933 patients were randomized to open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 μg/wk, or albIFN 900 or 1200 μg every 2 weeks for 24 weeks, each administered with oral ribavirin 800 mg/day. The primary end point of the study was sustained virologic response (SVR) (HCV-RNA level, <15 IU/mL at week 48). During the study, the data monitoring committee recommended dose modification for all patients receiving albIFN 1200 μg to 900 μg, impacting 38% of this treatment arm.By intention-to-treat analysis, SVR rates were 84.8% (95% confidence interval, 80.4%-88.6%), 79.8% (95% confidence interval, 74.9%-84.1%), and 80.0% (95% confidence interval, 75.1%-84.3%) with Peg-IFNalfa-2a, and albIFN 900 and 1200 μg, respectively. The primary hypothesis of noninferiority of SVR was established for albIFN 900 μg (P = .009) and 1200 μg (P = .006). Independent positive predictors of SVR by multivariate regression analysis were pretreatment HCV-RNA level less than 400,000 IU/mL, age younger than 45 years, body mass index less than 30 kg/m(2), genotype 2, normal γ-glutamyl transpeptidase and increased alanine aminotransferase levels at baseline, fibrosis stage F0-F2, no steatosis, and Asian geographic region (Peg-IFNalfa-2a only). The 3 treatment groups showed similar rates of serious (7%-8%) and severe (13%-16%) adverse events, and discontinuations owing to adverse events (3.6%-5.5%).Albinterferon alfa-2b 900 μg every 2 weeks provides an alternative efficacious treatment option in patients with chronic HCV genotype 2 or 3." @default.
• W2147596827 created "2016-06-24" @default.
• W2147596827 creator A5028553992 @default.
• W2147596827 creator A5036622111 @default.
• W2147596827 creator A5036970294 @default.
• W2147596827 creator A5046313503 @default.
• W2147596827 creator A5048947735 @default.
• W2147596827 creator A5052834447 @default.
• W2147596827 creator A5054070286 @default.
• W2147596827 creator A5058746547 @default.
• W2147596827 creator A5064179616 @default.
• W2147596827 creator A5064385070 @default.
• W2147596827 creator A5073695214 @default.
• W2147596827 creator A5074779832 @default.
• W2147596827 creator A5075322332 @default.
• W2147596827 creator A5086142040 @default.
• W2147596827 creator A5088683463 @default.
• W2147596827 creator A5089777411 @default.
• W2147596827 date "2010-10-01" @default.
• W2147596827 modified "2023-10-18" @default.
• W2147596827 title "Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3" @default.
• W2147596827 cites W1968955248 @default.
• W2147596827 cites W1970053808 @default.
• W2147596827 cites W1977076145 @default.
• W2147596827 cites W1981588917 @default.
• W2147596827 cites W1985241178 @default.
• W2147596827 cites W1989555992 @default.
• W2147596827 cites W2003104968 @default.
• W2147596827 cites W2020914906 @default.
• W2147596827 cites W2025812968 @default.
• W2147596827 cites W2027545702 @default.
• W2147596827 cites W2036083247 @default.
• W2147596827 cites W2038576929 @default.
• W2147596827 cites W2058538904 @default.
• W2147596827 cites W2063285149 @default.
• W2147596827 cites W2077816930 @default.
• W2147596827 cites W2086388926 @default.
• W2147596827 cites W2087829753 @default.
• W2147596827 cites W2094174828 @default.
• W2147596827 cites W2103942120 @default.
• W2147596827 cites W2106791445 @default.
• W2147596827 cites W2112876622 @default.
• W2147596827 cites W2115012618 @default.
• W2147596827 cites W2127685726 @default.
• W2147596827 cites W2146392601 @default.
• W2147596827 cites W2160234571 @default.
• W2147596827 cites W2164584401 @default.
• W2147596827 cites W4232907328 @default.
• W2147596827 cites W62862726 @default.
• W2147596827 doi "https://doi.org/10.1053/j.gastro.2010.06.062" @default.
• W2147596827 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3175757" @default.
• W2147596827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20600017" @default.
• W2147596827 hasPublicationYear "2010" @default.
• W2147596827 type Work @default.
• W2147596827 sameAs 2147596827 @default.
• W2147596827 citedByCount "74" @default.
• W2147596827 countsByYear W21475968272012 @default.
• W2147596827 countsByYear W21475968272013 @default.
• W2147596827 countsByYear W21475968272014 @default.
• W2147596827 countsByYear W21475968272015 @default.
• W2147596827 countsByYear W21475968272016 @default.
• W2147596827 countsByYear W21475968272017 @default.
• W2147596827 countsByYear W21475968272018 @default.
• W2147596827 countsByYear W21475968272019 @default.
• W2147596827 countsByYear W21475968272020 @default.
• W2147596827 countsByYear W21475968272021 @default.
• W2147596827 countsByYear W21475968272022 @default.
• W2147596827 crossrefType "journal-article" @default.
• W2147596827 hasAuthorship W2147596827A5028553992 @default.
• W2147596827 hasAuthorship W2147596827A5036622111 @default.
• W2147596827 hasAuthorship W2147596827A5036970294 @default.
• W2147596827 hasAuthorship W2147596827A5046313503 @default.
• W2147596827 hasAuthorship W2147596827A5048947735 @default.
• W2147596827 hasAuthorship W2147596827A5052834447 @default.
• W2147596827 hasAuthorship W2147596827A5054070286 @default.
• W2147596827 hasAuthorship W2147596827A5058746547 @default.
• W2147596827 hasAuthorship W2147596827A5064179616 @default.
• W2147596827 hasAuthorship W2147596827A5064385070 @default.
• W2147596827 hasAuthorship W2147596827A5073695214 @default.
• W2147596827 hasAuthorship W2147596827A5074779832 @default.
• W2147596827 hasAuthorship W2147596827A5075322332 @default.
• W2147596827 hasAuthorship W2147596827A5086142040 @default.
• W2147596827 hasAuthorship W2147596827A5088683463 @default.
• W2147596827 hasAuthorship W2147596827A5089777411 @default.
• W2147596827 hasBestOaLocation W21475968272 @default.
• W2147596827 hasConcept C126322002 @default.
• W2147596827 hasConcept C168563851 @default.
• W2147596827 hasConcept C203014093 @default.
• W2147596827 hasConcept C203092338 @default.
• W2147596827 hasConcept C2522874641 @default.
• W2147596827 hasConcept C2776408679 @default.
• W2147596827 hasConcept C2776461080 @default.
• W2147596827 hasConcept C2778606649 @default.
• W2147596827 hasConcept C2780040827 @default.
• W2147596827 hasConcept C44249647 @default.
• W2147596827 hasConcept C71924100 @default.
• W2147596827 hasConcept C90924648 @default.
• W2147596827 hasConceptScore W2147596827C126322002 @default.

• next